SAN CARLOS, Calif.--(BUSINESS WIRE)--BioCardia®, Inc. [OTC:BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that it is scheduled to present at the 5th Annual Cell & Gene Therapy Investor Day that is being held on April 27, 2017 at The State Room in Boston, MA.
BioCardia is scheduled to present in The Great Room at 11:25 am EST.
BioCardia, Inc., headquartered in San Carlos, CA, is developing regenerative biologic therapies to treat cardiovascular disease. CardiAMP® and CardiALLO® cell therapies are the company’s biotherapeutic product candidates in clinical development. The Company's current products include the Helix™ transendocardial delivery system and the Morph® steerable guide and sheath catheter portfolio. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and clinical support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction.